Literature DB >> 2581591

Studies on hydroxyethyl starch. Part II: Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers.

H P Ferber, E Nitsch, H Förster.   

Abstract

32 volunteers, none of whom showed any symptoms for kidney, liver or pancreas disease, were given by infusion 500 ml of various type of hydroxyethyl starch (HES) at a concentration of 6% (450/0.7, 450/0.5, 450/0.3, 300/0.4) as well as of 10% (200/0.7, 200/0.5, 200/0.3, 200/0.1) over a period of 30 min. After infusion both the Mw and the Mn diminished. The rate of elimination of HES from serum entirely depended on molar substitution and not on Mw. The quotient Mw/Mn decreased considerably over the entire test period. The lower molecular weight limit in serum remained relatively the same at 60,000 Daltons. Maximum molecular weight limit of urine, too, was 60,000 Daltons.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581591

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

Review 1.  Pharmacokinetics of hydroxyethyl starch.

Authors:  Cornelius Jungheinrich; Thomas A Neff
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.

Authors:  Romuald Bellmann; Clemens Feistritzer; Christian J Wiedermann
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

3.  Low molecular weight hydroxyethyl starch 6% compared to albumin 4% during intentional hemodilution.

Authors:  J F Baron; D De Kegel; A C Prost; O Mundler; M Arthaud; G Basset; G Maistre; F Masson; A Carayon; C Landault
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).

Authors:  A C Degrémont; M Ismaïl; M Arthaud; B Oulare; O Mundler; M Paris; J F Baron
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

5.  Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers.

Authors:  J Waitzinger; F Bepperling; G Pabst; J Opitz; M Müller; J François Baron
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 6.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

7.  Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5.

Authors:  H Kroemer; A Haass; K Müller; H Jäger; E M Wagner; P Heimburg; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Fluid resuscitation in sepsis: reexamining the paradigm.

Authors:  Poorna Madhusudan; Bharath Kumar Tirupakuzhi Vijayaraghavan; Matthew Edward Cove
Journal:  Biomed Res Int       Date:  2014-08-11       Impact factor: 3.411

Review 9.  Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review.

Authors:  Christian J Wiedermann; Michael Joannidis
Journal:  Intensive Care Med       Date:  2013-11-21       Impact factor: 17.440

10.  Assessment of Hydroxyethyl Starch (6% HES 130/0.4) Kidney Storage in Critically Ill Dogs: A Post-mortem Prospective Study.

Authors:  Katja-Nicole Adamik; Michael H Stoffel; Simone Tangermann; Bettina de Breuyn Dietler; Nadine Stokar-Regenscheit
Journal:  Front Vet Sci       Date:  2022-01-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.